Zoledronate is active against imatinib mesylate-resistant chronic myeloid leukemia cell lines and synergistic/additive when combined with imatinib mesylate.

Proceedings article published in 2003 by C. Chuah, Aj Tipping, Jm Goldman, Jv Melo

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Preprint: policy unknown

Upload

Postprint: policy unknown

Upload

Published version: policy unknown

Upload